A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.
D000328:Adult; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis*; D002985:Clinical Protocols; D015316:Genetic Therapy; D015789:HLA-A2 Antigen / Q000032:analysis*; D006650:Histocompatibility Testing; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D016233:Immunotherapy, Active / Q000379:methods*; D015994:Incidence; D007258:Informed Consent; D007376:Interleukin-2 / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D008545:Melanoma / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D010865:Pilot Projects; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D012449:Safety; D016879:Salvage Therapy; D014161:Transduction, Genetic; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*
D000951:Antigens, Neoplasm; D015789:HLA-A2 Antigen; D007155:Immunologic Factors; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins